Cost-effectiveness of alirocumab in patients with acute coronary syndromes: the ODYSSEY OUTCOMES trial
10.1016/j.jacc.2020.03.029 · doi-reference
Cost-effectiveness of alirocumab: a just-in-time analysis based on the ODYSSEY outcomes trial
10.7326/m18-1776 · doi-reference
PCSK9 inhibitors: economics and policy
10.1016/j.jacc.2017.10.001 · doi-reference
Cardiac allograft vasculopathy inhibition with alirocumab: the CAVIAR trial
10.1161/circulationaha.125.077603 · doi-reference
Long-term lipid lowering with evolocumab in older individuals
10.1016/j.jacc.2024.11.019 · doi-reference
Predictors of PCSK9 (proprotein convertase Subtilisin/Kexin type 9) inhibitor prescriptions for secondary prevention of clinical atherosclerotic cardiovascular disease
10.1161/circoutcomes.120.007237 · doi-reference
Effects of evolocumab on low-density lipoprotein cholesterol, non-high density lipoprotein cholesterol, apolipoprotein B, and lipoprotein(a) by race and ethnicity: a meta-analysis of individual participant data from double-blind and open-label extension studies
10.1161/jaha.120.016839 · doi-reference
Factors associated with PCSK9 inhibitor initiation among US veterans
10.1161/jaha.120.019254 · doi-reference
Adoption of PCSK9 inhibitors among patients with atherosclerotic disease
10.1161/jaha.120.019331 · doi-reference
Race/ethnic and sex differences in the initiation of Non-statin lipid-lowering medication following myocardial infarction
10.1016/j.jacl.2021.08.001 · doi-reference
Alirocumab and cardiovascular outcomes according to sex and lipoprotein(a) after acute coronary syndrome: a report from the ODYSSEY OUTCOMES study
10.1016/j.jacl.2024.04.122 · doi-reference
Sex difference in circulating PCSK9 and its clinical implications
10.3389/fphar.2022.953845 · doi-reference
Sex-specific predictors of PCSK9 levels in a European population: the IMPROVE study
10.1016/j.atherosclerosis.2020.07.014 · doi-reference
Sex differences in the treatment with PCSK9 monoclonal antibodies-real world experience from a dedicated preventive cardiology clinic
10.1016/j.ajpc.2025.101022 · doi-reference
Lower on-treatment low-density lipoprotein cholesterol and major adverse cardiovascular events in women and men: pooled analysis of 10 ODYSSEY phase 3 alirocumab trials
10.1161/jaha.118.009221 · doi-reference
Sex differences in low-density lipoprotein cholesterol reduction with PCSK9 inhibitors in real-world patients: the LIPID-REAL registry
10.1097/fjc.0000000000001205 · doi-reference
Sex differences in LDL-C response to PCSK9 inhibitors: a real world experience
10.1016/j.jacl.2022.12.002 · doi-reference
Sex differences in efficacy and safety of PCSK9 monoclonal antibodies: a real-world registry
10.1016/j.atherosclerosis.2023.03.013 · doi-reference
PCSK9-targeting drugs and gender: are there any differences?
10.3390/jcm14134469 · doi-reference
LDL-cholesterol lowering with evolocumab, and outcomes according to age and sex in patients in the FOURIER trial
10.1177/2047487320902750 · doi-reference
Efficacy and safety of oral PCSK9 inhibitor enlicitide in adults with heterozygous familial hypercholesterolemia: a randomized clinical trial
10.1001/jama.2025.20620 · doi-reference
Phase 2b randomized trial of the oral PCSK9 inhibitor MK-0616
10.1016/j.jacc.2023.02.018 · doi-reference
Oral PCSK9 inhibitors
10.1007/s11883-024-01199-2 · doi-reference
Design and rationale of a randomized clinical trial assessing the effect of inclisiran on atherosclerotic plaque in individuals without previous cardiovascular event and without flow- limiting lesions identified in an in-hospital screening: the VICTORION-PLAQUE primary prevention trial
10.1016/j.ahj.2025.08.001 · doi-reference
Design and rationale of the VICTORION-difference study: a phase 4 randomized, double-blind, placebo-controlled clinical trial to assess inclisiran's early efficacy, safety, tolerability, as well as its impact on quality of life in individuals with hypercholesterolemia
10.1016/j.ahj.2025.05.014 · doi-reference
LDL-C management with inclisiran plus usual care vs usual care alone in participants with recent acute coronary syndrome: victorion-inception
10.1016/j.jacl.2025.04.157 · doi-reference
Safety and lipid-lowering efficacy of inclisiran monotherapy in patients without ASCVD: the VICTORION-mono randomized clinical trial
10.1016/j.jacc.2025.04.049 · doi-reference
Efficacy and safety of very low achieved LDL-cholesterol in patients with prior ischemic stroke
10.1161/circulationaha.125.077549 · doi-reference
Obesity-associated cardiovascular risk and benefit from PCSK9 inhibition: a prespecified analysis from FOURIER
10.1016/j.jacc.2025.10.036 · doi-reference
Low-density lipoprotein cholesterol lowering with evolocumab and outcomes in patients with peripheral artery disease: insights from the FOURIER trial (further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk)
10.1161/circulationaha.117.032235 · doi-reference
Peripheral artery disease and venous thromboembolic events after acute coronary syndrome: role of lipoprotein(a) and modification by alirocumab: prespecified analysis of the ODYSSEY OUTCOMES randomized clinical trial
10.1161/circulationaha.120.046524 · doi-reference
Effect of alirocumab on lipoprotein(a) and cardiovascular risk after acute coronary syndrome
10.1016/j.jacc.2019.10.057 · doi-reference
